The subject of the acquisition include
Low molecular weight heparins (B01AB04, B01AB05 and B01AB10),
Monoclonal antibodies (L01F), in this group excluding L01FC01
Tumor necrosis factor alpha inhibitors (L04AB)
Lenalidomidi (L04AX04)
Artikaiini, yhdistelmävalmisteet (N01BB58)
For the contract period 1.4.2023- 31.3.2024 + one (1) option year (1.4.2024-31.3.2025)
Low molecular weight heparins (B01AB04, B01AB05 and B01AB10)One part of this acquisition is low molecular weight heparins (B01AB04, B01AB05 and B01AB10)
Monoclonal antibodies (L01F), excluding L01FC01 from the L01F group.One part of this procurement is Monoclonal Antibodies (L01F), excluding L01FC01 from the L01F group.
Tumor necrosis factor alpha inhibitors (L04AB)One aspect of this procurement is Tumour necrosis factor alfa inhibitors (L04AB)
Lenalidomidi (L04AX04)One aspect of this acquisition is Lenalidomide (L04AX04)
Artikaiini, yhdistelmävalmisteet (N01BB58)One aspect of this procurement is Articin, composite products (N01BB58)